Drug intelligence / Profile preview

NRX-NGT009

Development stage: Preclinical
Lead developer: Novorex
Modality: Small Molecules
Administration: Oral

Overview

NRX-NGT009 is an investigational small molecule therapeutic being developed by Novorex for the treatment of psoriasis. Discovered using Novorex's proprietary fragment-based drug discovery (FBDD) and artificial intelligence (AI) platform, the drug is designed as an oral small molecule alternative to expensive biologic therapies (a "Big to Small" or BTS strategy). As of 2026, NRX-NGT009 is in the lead optimization/preclinical stage of development, with plans to enter IND-enabling preclinical studies.

Beyond the preview

Go deeper on NRX-NGT009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRX-NGT009.

Explore the full profile